273 related articles for article (PubMed ID: 30975896)
1. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.
Broggi MAS; Maillat L; Clement CC; Bordry N; Corthésy P; Auger A; Matter M; Hamelin R; Potin L; Demurtas D; Romano E; Harari A; Speiser DE; Santambrogio L; Swartz MA
J Exp Med; 2019 May; 216(5):1091-1107. PubMed ID: 30975896
[TBL] [Abstract][Full Text] [Related]
2. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and
García-Silva S; Benito-Martín A; Sánchez-Redondo S; Hernández-Barranco A; Ximénez-Embún P; Nogués L; Mazariegos MS; Brinkmann K; Amor López A; Meyer L; Rodríguez C; García-Martín C; Boskovic J; Letón R; Montero C; Robledo M; Santambrogio L; Sue Brady M; Szumera-Ciećkiewicz A; Kalinowska I; Skog J; Noerholm M; Muñoz J; Ortiz-Romero PL; Ruano Y; Rodríguez-Peralto JL; Rutkowski P; Peinado H
J Exp Med; 2019 May; 216(5):1061-1070. PubMed ID: 30975894
[TBL] [Abstract][Full Text] [Related]
3. Postlymphadenectomy Analysis of Exosomes from Lymphatic Exudate/Exudative Seroma of Melanoma Patients.
García-Silva S; Ximénez-Embún P; Muñoz J; Peinado H
Methods Mol Biol; 2021; 2265():345-359. PubMed ID: 33704726
[TBL] [Abstract][Full Text] [Related]
4. Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer.
Ekström K; Crescitelli R; Pétursson HI; Johansson J; Lässer C; Olofsson Bagge R
BMC Cancer; 2022 Jan; 22(1):50. PubMed ID: 35012489
[TBL] [Abstract][Full Text] [Related]
5. The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status.
Sahni D; Robson A; Orchard G; Szydlo R; Evans AV; Russell-Jones R
J Clin Pathol; 2005 Jul; 58(7):715-21. PubMed ID: 15976338
[TBL] [Abstract][Full Text] [Related]
6. Surgical damage to the lymphatic system promotes tumor growth via impaired adaptive immune response.
Nakamura Y; Fujisawa Y; Okiyama N; Watanabe R; Tanaka R; Ishitsuka Y; Tahara H; Fujimoto M
J Dermatol Sci; 2018 Apr; 90(1):46-51. PubMed ID: 29352630
[TBL] [Abstract][Full Text] [Related]
7. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
[TBL] [Abstract][Full Text] [Related]
8. Selective lymph node dissection in patients with intermediate thickness melanoma: our experience.
Cafiero F; Peressini A; Percivale PL; Rainero ML; Faggioni M; Gipponi M; Queirolo P; Nicolo G; Bertoglio S
Anticancer Res; 2000; 20(1B):497-500. PubMed ID: 10769712
[TBL] [Abstract][Full Text] [Related]
9. Tumor lymphangiogenesis and melanoma metastasis.
Rinderknecht M; Detmar M
J Cell Physiol; 2008 Aug; 216(2):347-54. PubMed ID: 18481261
[TBL] [Abstract][Full Text] [Related]
10. Intraoperative application of fibrin sealant does not reduce the duration of closed suction drainage following radical axillary lymph node dissection in melanoma patients: a prospective randomized trial in 58 patients.
Neuss H; Raue W; Koplin G; Schwenk W; Reetz C; Mall JW
World J Surg; 2008 Jul; 32(7):1450-5. PubMed ID: 18373121
[TBL] [Abstract][Full Text] [Related]
11. Innate extracellular vesicles from melanoma patients suppress β-catenin in tumor cells by miRNA-34a.
Lee JH; Dindorf J; Eberhardt M; Lai X; Ostalecki C; Koliha N; Gross S; Blume K; Bruns H; Wild S; Schuler G; Vera J; Baur AS
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30846484
[TBL] [Abstract][Full Text] [Related]
12. Serum S100--a marker for disease monitoring in metastatic melanoma.
Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
[TBL] [Abstract][Full Text] [Related]
13. A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma.
Damude S; Wevers KP; Murali R; Kruijff S; Hoekstra HJ; Bastiaannet E
Eur J Surg Oncol; 2017 Sep; 43(9):1753-1759. PubMed ID: 28797756
[TBL] [Abstract][Full Text] [Related]
14. Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.
Pastushenko I; Van den Eynden GG; Vicente-Arregui S; Prieto-Torres L; Alvarez-Alegret R; Querol I; Dirix LY; Carapeto FJ; Vermeulen PB; Van Laere SJ
Am J Dermatopathol; 2016 May; 38(5):338-46. PubMed ID: 26909582
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
[TBL] [Abstract][Full Text] [Related]
16. Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma.
Scheri RP; Essner R
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1105-10. PubMed ID: 16831081
[TBL] [Abstract][Full Text] [Related]
17. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients.
Damude S; Hoekstra HJ; Bastiaannet E; Muller Kobold AC; Kruijff S; Wevers KP
Eur J Surg Oncol; 2016 Apr; 42(4):545-51. PubMed ID: 26831006
[TBL] [Abstract][Full Text] [Related]
18. Lymphatic mapping and sentinel lymph node biopsy in the management of primary cutaneous melanoma: report of a single-centre experience.
Cecchi R; De Gaudio C; Buralli L; Innocenti S
Tumori; 2006; 92(2):113-7. PubMed ID: 16724689
[TBL] [Abstract][Full Text] [Related]
19. Gamma probe-directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: Reliability of the procedure and analysis of failures after long-term follow-up.
Jacobs IA; Chevinsky AH; Swayne LC; Magidson JG; Britto EJ; Smith TJ
J Surg Oncol; 2001 Jul; 77(3):157-64. PubMed ID: 11455551
[TBL] [Abstract][Full Text] [Related]
20. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
